Skip to main content
Premium Trial:

Request an Annual Quote

On the Decline

The Wall Street Journal's Health Blog has put together a chart of R&D spending by US drug companies — a related article in the paper said that R&D fell in 2009 by 3.8 percent to $382.6 billion. Pfizer and Johnson and Johnson's spending dropped by 10.8 and 12.7 percent, respectively while the other companies showed gains in spending. For 2010, R&D funding is expected to rise, but the Health Blog warns that the numbers don't give the full picture. "For example, Pfizer's R&D spending may climb next year because of the Wyeth acquisition, but continuing cuts could mean the company's R&D spending is lower than this year's combined R&D spending for Pfizer and Wyeth," the blog says.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.